Targeted Lipid Nanoparticles for Antisense Oligonu... - BV FAPESP
Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Targeted Lipid Nanoparticles for Antisense Oligonucleotide Delivery

Full text
Author(s):
Petrilli, Raquel [1, 2] ; Eloy, Josimar O. [1, 2] ; Marchetti, Juliana M. [1] ; Lopez, Renata F. V. [1] ; Lee, Robert J. [1, 2]
Total Authors: 5
Affiliation:
[1] Univ Sao Paulo, Sch Pharmaceut Sci, BR-14049 Ribeirao Preto, SP - Brazil
[2] Ohio State Univ, Coll Pharm, Columbus, OH 43210 - USA
Total Affiliations: 2
Document type: Journal article
Source: CURRENT PHARMACEUTICAL BIOTECHNOLOGY; v. 15, n. 9, p. 847-855, 2014.
Web of Science Citations: 9
Abstract

Antisense oligonucleotides (AS-ODNs) are short, single-stranded DNA molecules designed to bind specifically to a target messenger RNA (mRNA) and down-regulate gene expression. Despite being a promising class of therapeutics for a variety of diseases, they face major hurdles limiting their clinical application, including low intracellular delivery and poor in vivo stability. Among strategies available to enhance delivery, lipid nanoparticles have gained considerable attention. Active targeting of carriers of AS-ODNs is likely to further enhance delivery efficiency. For that, ligands for overexpressed receptors on the cell surface can be linked to the lipid nanoparticle, facilitating intracellular uptake, resulting in improved efficacy and reduced systemic toxicity. These include cell penetrating peptides (CPPs), transferrin, folate, oligosaccharides, polysaccharides and antibodies. Although targeted-lipid nanoparticles have been shown to enhance intracellular delivery and therapeutic effect of AS-ODNs, no clinical evaluation has been conducted yet. Therefore, more efforts are needed to turn these promising tools into clinical products. (AU)

FAPESP's process: 12/10388-3 - Liposomes and immunoliposomes containing anticancer drugs: development, characterization and efficacy evaluation against breast cancer
Grantee:Josimar de Oliveira Eloy
Support Opportunities: Scholarships in Brazil - Doctorate
FAPESP's process: 13/05362-8 - Functionalization of liposomes containing metformin and paclitaxel with trastuzumab: development, characterization and evaluation of efficacy against breast cancer
Grantee:Josimar de Oliveira Eloy
Support Opportunities: Scholarships abroad - Research Internship - Doctorate
FAPESP's process: 13/15134-2 - Preparation of immunoliposomes for topical skin cancer treatment
Grantee:Raquel Petrilli
Support Opportunities: Scholarships abroad - Research Internship - Doctorate
FAPESP's process: 12/23764-3 - Topical application of liposomes containing Cetuximab: the effect of physical skin penetration enhancement techniques for cutaneous squamous cell carcinoma
Grantee:Raquel Petrilli
Support Opportunities: Scholarships in Brazil - Doctorate